Anemia in Chronic obstructive pulmonary disease: Prevalence, pathogenesis, and potential impact

Lung India

Volumn 32, Issue 2, 2015, Pages 142-151

  Sarkar, Malay ^a   Rajta, Puja Negi ^a   Khatana, Jasmin ^a  

^a INDIRA GANDHI MEDICAL COLLEGE   (India)

Author keywords

anemia; Anemia of chronic disease; chronic obstructive pulmonary disease

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; HEPCIDIN; INTERLEUKIN 1; INTERLEUKIN 6; IRON; TESTOSTERONE; THEOPHYLLINE;

ANEMIA; ANEMIA OF CHRONIC DISEASE; BONE MARROW; BONE MARROW DISEASE; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE ASSOCIATION; ERYTHROCYTE; ERYTHROCYTE LIFESPAN; ERYTHROCYTOSIS; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; FORCED EXPIRATORY VOLUME; FUNCTIONAL STATUS; HEALTH CARE UTILIZATION; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; HYPOGONADISM; IRON METABOLISM; IRON METABOLISM DISORDER; KIDNEY DYSFUNCTION; LUNG MINUTE VOLUME; MEGALOCYTOSIS; MORTALITY; NONHUMAN; PATHOGENESIS; PREVALENCE; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 84925259214     PISSN: 09702113     EISSN: 0974598X     Source Type: Journal    
DOI: 10.4103/0970-2113.152626     Document Type: Review

References (95)

1. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J RespirCrit Care Med 2013;187:347-65.
2. Decramer M, Rennard S, Troosters T, Mapel DW, Giardino N, Mannino D, et al. COPD as a lung disease with systemic consequences - Clinical impact, mechanisms, and potential for early intervention. COPD 2008;5:235-56.
3. Fabbri LM, Rabe KF.From COPD to chronic systemic inflammatory syndrome? Lancet 2007;370:797-9.
4. Barnes PJ, Celli BR.Systemic manifestations and comorbidities of COPD. EurRespir J 2009;33:1165-85.
5. Zieliński J. Effects of long-term oxygen therapy in patients with chronic obstructive pulmonary disease. CurrOpinPulm Med 1999;5:81-7.
6. Boutou AK, Stanopoulos I, Pitsiou GG, Kontakiotis T, Kyriazis G, Sichletidis L, et al. Anemia of chronicdiseasein chronic obstructive pulmonarydisease: A case-control study of cardiopulmonary exercise responses.Respiration 2011;82:237-45.
7. Nutritional anaemias.Report of a WHO scientific group. World Health Organ TechRep Ser 1968;405:5-37.
8. John M, Hoernig S, Doehner W, Okonko DD, Witt C, Anker SD.Anemia and inflammation in COPD. Chest 2005;127:825-9.
9. Halpern MT, Zilberberg MD, Schmier JK, Lau EC, Shorr AF. Anemia, costs and mortality in chronic obstructive pulmonary disease. Cost EffResourAlloc 2006;4:17.
10. Parveen S, Rangreze I, Ahmad SN, Mufti SA, Khan SS. Prevalence of anemia in patients with COPD and its potential impact on morbidity of COPD patients. Int J Clin Med 2014;5:452-8.
11. Shorr AF, Doyle J, Stern L, Dolgitser M, Zilberberg MD. Anemia in chronic obstructive pulmonary disease: Epidemiology and economic implications. Curr Med Res Opin 2008;24:1123-30.
12. John M, Lange A, Hoernig S, Witt C, Anker SD. Prevalence of anemia in chronic obstructive pulmonary disease: Comparison to other chronic diseases.Int J Cardiol 2006;111:365-70.
13. Chambellan A, Chailleux E, Similowski T; ANTADIR Observatory Group. Prognostic value of the hematocrit in patients with severe COPD receiving long-term oxygen therapy. Chest 2005;128:1201-8.
14. Krishnan G, Grant BJ, Muti PC, Mishra A, Ochs-Balcom HM, Freudenheim JL, et al. Association between anemia and quality of life in a population sample of individuals with chronic obstructive pulmonary disease. BMC Pulm Med 2006;6:23.
15. Cote C, Zilberberg MD, Mody SH, Dordelly LJ, Celli B. Haemoglobin level and its clinical impact in a cohort of patients with COPD. EurRespir J 2007;29:923-9.
16. Attaran D, Khajedalouee M, Ahmadi F, Rezaeitalab F, Towhidi M, Asnaashari A, et al.Anemia in COPD patients and its relation to serum levels of erythropoietin.Tanaffos2009;8:11-6.
17. Silverberg DS, Mor R, Weu MT, Schwartz D, Schwartz IF, Chernin G. Anemia and iron deficiency in COPD patients: Prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron. BMC Pulm Med 2014;14:24.
18. Chambellan A, Coulon S, Cavailles A, Hermine O, Similowski T. COPD and erythropoiesis: Interactions and consequences. Rev Mal Respir 2012;29:213-31.
19. Anía BJ, Suman VJ, Fairbanks VF, Rademacher DM, Melton LJ 3rd. Incidence of anemia in older people: An epidemiologic study in a well defined population. J Am GeriatrSoc 1997;45:825-31.
20. Chellan R, Paul L. Prevalence of iron-deficiency anemia in India: Results from a large nationwide survey. J PopulSoc Stud2010;19:59-80.
21. Portillo K, Martinez-Rivera C, Ruiz-Manzano J.Anaemiainchronic obstructive pulmonary disease. Does it reallymatter?Int J ClinPract 2013;67:558-65.
22. Carroz KP. Anemiain COPD: Should it betaken into consideration? Arch Bronconeumol 2007;43:392-8.
23. Shah YM, Xie L. Hypoxia-inducible factors link iron homeostasis and erythropoiesis. Gastroenterology2014;146:630-42.
24. Weiss G, Goodnough LT. Anemiaofchronicdisease. N Engl J Med2005;352:1011-23.
25. Roy CN. Anemia of inflammation. Hematology Am SocHematolEduc Program2010;2010:276-80.
26. Cartwright GE. The anemia of chronic disorders. SeminHematol 1966;3:351-75.
27. Poggiali E, Migone De Amicis M, Motta I. Anemiaofchronicdisease: Auniquedefectofironrecyclingformanydifferentchronic diseases. Eur J Intern Med2014;25:12-7.
28. Krause A, Neitz S, Mägert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett2000;480:147-50.
29. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003;101:2461-3.
30. Liu XB, Nguyen NB, Marquess KD, Yang F, Haile DJ.Regulation of hepcidin and ferroportin expression by lipopolysaccharide in splenic macrophages. Blood Cells Mol Dis2005;35:47-56.
31. Bekri S, Gual P, Anty R, Luciani N, Dahman M, Ramesh B, et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 2006;131:788-96.
32. Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B, et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. ProcNatlAcadSci U S A 2002;99:4596-601.
33. Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. ProcNatlAcadSci U S A 2001;98:8780-5.
34. Ganz T, Nemeth E.Hepcidin and disorders of iron metabolism. Annu Rev Med 2011;62:347-60.
35. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-3.
36. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-6.
37. Armitage AE, Eddowes LA, Gileadi U, Cole S, Spottiswoode N, Selvakumar TA, et al.Hepcidin regulation by innate immune and infectious stimuli. Blood 2011;118:4129-39.
38. Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005;106:1864-6.
39. Raj DS. Role of interleukin-6 in the anemia of chronic disease.Semin Arthritis Rheum 2009;38:382-8.
40. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood 2006;108:3204-9.
41. Inamura J, Ikuta K, Jimbo J, Shindo M, Sato K, Torimoto Y, et al. Upregulation of hepcidin by interleukin-1betain human hepatoma cell lines. Hepatol Res 2005;33:198-205.
42. Findlay JW, Smith WC, Lee JW, Nordblom GD, Das I, DeSilva BS, et al. Validation of immunoassaysforbio analysis: Apharmaceutical industryperspective.J Pharm Biomed Anal 2000;21:1249-73.
43. Brailly H, Montero-Julian FA, Zuber CE, Flavetta S, Grassi J, Houssiau F, et al. Total interleukin-6 in plasma measured by immunoassay. Clin Chem 1994;40:116-23.
44. Thompson DK, Hu f fman KM, Kr aus WE, Kr aus VB. CriticalappraisaloffourIL-6immunoassays. PLoS One2012;7:e30659.
45. Maes K, Nemeth E, Roodman GD, Huston A, Esteve F, Freytes C, et al. Inanemia of multiplemyeloma, hepcidinisinduced by increased bone morphogenetic protein 2. Blood 2010;116:3635-44.
46. Besson-Fournier C, Latour C, Kautz L, Bertrand J, Ganz T, Roth MP, et al. InductionofactivinBbyinflammatorystimuliup - regulatesexpressionof theiron - regulatorypeptidehepcidin through Smad 1/5/8 signaling. Blood2012;120:431-9.
47. Duru S, Bilgin E, Ardic¸ S.Hepcidin: A useful marker inchronic obstructive pulmonary disease. Ann Thorac Med 2012;7:31-5.
48. Mumby S, Adcock IM, Chung K, Quinlan GJ; Critical Care. Serum hepcidin levels are elevated in COPD and are associated with increased intracellular iron in the lung. Am J RespirCrit Care Med 2012;185:A6769.
49. Kemna EH, Kartikasari AE, van Tits LJ, Pickkers P, Tjalsma H, Swinkels DW. Regulation of hepcidin: Insights from biochemical analyses on human serum samples. Blood Cells Mol Dis 2008;40:339-46.
50. Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005;106:1864-6.
51. Brookes MJ, Sharma NK, Tselepis C, Iqbal TH. Serum pro-hepcidin: Measuring active hepcidin or a non-functional precursor? Gut 2005;54:169-70.
52. Roe MA, Spinks C, Heath AL, Harvey LJ, Foxall R, Wimperis J, et al. Serum prohepcidin concentration: No association with iron absorption in healthy men; and no relationship with iron status in men carrying HFE mutations, hereditary haemochromatosis patients undergoing phlebotomy treatment, or pregnant women. Br J Nutr 2007;97:544-9.
53. Sasu BJ, Li H, Rose MJ, Arvedson TL, Doellgast G, Molineux G. Serum hepcidin but not prohepcidin may be an effective marker for anemia of inflammation (AI).Blood Cells Mol Dis 2010;45:238-45.
54. Gagliardo B, Kubat N, Faye A, Jaouen M, Durel B, Deschemin JC, et al. Pro-hepcidin is unable to degrade the iron exporter ferroportin unless maturated by a furin-dependent process.J Hepatol 2009;50:394-401.
55. Kroot JJ, Kemna EH, Bansal SS, Busbridge M, Campostrini N, Girelli D, et al. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: Need for standardization. Haematologica 2009;94:1748-52.
56. Jelkmann W. Pro-inflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998;18:555-9.
57. Means RTJr, Krantz SB. Inhibition of human erythroid colony-forming units by gamma interferon can be corrected by recombinant human erythropoietin. Blood 1991;78:2564-7.
58. Boutou AK, Pitsiou GG, Stanopoulos I, Kontakiotis T, Kyriazis G, Argyropoulou P. Levels of inflammatory mediators in chronic obstructive pulmonary disease patients with anemia of chronic disease: A case-control study. QJM 2012;105:657-63.
59. El-Korashy RI, Amin YM, Moussa HA, Badawy I, Bakr SM. Study the relationship of erythropoietin and chronic obstructive pulmonary disease. Egypt. J. Chest Dis.Tuberc 2012;61:53-7.
60. Markoulaki D, Kostikas K, Papatheodorou G, Koutsokera A, Alchanatis M, Bakakos P, et al. Hemoglobin, erythropoietin and systemic inflammation in exacerbations of chronic obstructive pulmonary disease.Eur J Intern Med 2011;22:103-7.
61. Spivak JL. Iron and the anemia of chronic disease. Oncology (Williston Park) 2002;16 Suppl 10:25-33.
62. Rice L, Alfrey CP, Driscoll T, Whitley CE, Hachey DL, Suki W. Neocytolysis contributes to the anemia of renal disease. Am J Kidney Dis 1999;33:59-62.
63. Moldawer LL, Marano MA, Wei H, Fong Y, Silen ML, Kuo G, et al. Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo. FASEB J 1989;3:1637-43.
64. Incalzi RA, Corsonello A, Pedone C, Battaglia S, Paglino G, Bellia V; Extrapulmonary Consequences of COPD in the Elderly Study Investigators. Chronic renal failure: A neglected comorbidity of COPD. Chest 2010;137:831-7.
65. Elmahallawy II, Qora MA. Prevalence of chronic renal failure in COPD patients. Egypt. J. Chest Dis. Tuberc 2013;62:221-7.
66. Ble A, Fink JC, Woodman RC, Klausner MA, Windham BG, Guralnik JM, et al. Renal function, erythropoietin, and anemia of older persons: The InCHIANTI study. Arch Intern Med 2005;165:2222-7.
67. Vlahakos DV, Marathias KP, Madias NE. The role of the renin-angiotensin system in the regulation of erythropoiesis. Am J Kidney Dis 2010;56:558-65.
68. Vlahakos DV, Kosmas EN, Dimopoulou I, Ikonomou E, Jullien G, Vassilakos P, et al. Association between activation of the renin-angiotensin system and secondary erythrocytosis in patients with chronic obstructive pulmonary disease. Am J Med 1999;106:158-64.
69. Marathias KP, Agroyannis B, Mavromoustakos T, Matsoukas J, Vlahakos DV. Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers.Curr Top Med Chem 2004;4:483-6.
70. Ueno M, Brookins J, Beckman BS, Fisher JW. A1 and A2 adenosine receptor regulation of erythropoietin production. Life Sci 1998;43:229-37.
71. Tsantes AE, Tassiopoulos ST, Papadhimitriou SI, Bonovas S, Poulakis N, Vlachou A, et al. Theophylline treatment may adversely affect the anoxia-induced erythropoietic response without suppressing erythropoietin production. Eur J Clin Pharmacol 2003;59:379-83.
72. Van Vliet M, Spruit MA, Verleden G, Kasran A, Van Herck E, Pitta F, et al. Hypogonadism, quadriceps weakness, and exercise intolerance in chronic obstructive pulmonary disease. Am J RespirCrit Care Med 2005;172:1105-11.
73. Laghi F, Antonescu-Turcu A, Collins E, Segal J, Tobin DE, Jubran A, et al. Hypogonadism in men with chronic obstructive pulmonary disease: Prevalence and quality of life. Am J RespirCrit Care Med 2005;171:728-33.
74. Kamischke A, Kemper DE, Castel MA, Lüthke M, Rolf C, Behre HM, et al. Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. EurRespir J 1998;11:41-5.
75. Debigaré R, Marquis K, Côté CH, Tremblay RR, Michaud A, LeBlanc P, et al. Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest 2003;124:83-9.
76. Ferrucci L, Maggio M, Bandinelli S, Basaria S, Lauretani F, Ble A, et al. Lowtestosteronelevels and the risk ofanemia in oldermen and women. Arch Intern Med 2006;166:1380-8.
77. Vlahakos DV, Marathias KP, Agroyannis B, Madias NE. Post transplant erythrocytosis. Kidney Int 2003;63:1187-94.
78. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996;334:835-40.
79. Negi H, Sarkar M, Raval AD, Pandey K, Das P. Health-related quality of life in patients with chronic obstructive pulmonary disease in North India. J Postgrad Med 2014;60:7-11.
80. Valderramas S, Camelier AA, Silva SA, Mallmann R, de Paulo HK, Rosa FW. Reliability of the Brazilian Portuguese version of the fatigue severity scale and its correlation with pulmonary function, dyspnea, and functional capacity in patients with COPD. J Bras Pneumol 2013;39:427-33.
81. Barba R, de Casasola GG, Marco J, Emilio Losa J, Plaza S, Canora J, et al. Anemia in chronic obstructive pulmonary disease: A readmission prognosis factor. Curr Med Res Opin 2012;28:617-22.
82. Martinez-Rivera C, Portillo K, Muñoz-Ferrer A, Martínez-Ortiz ML, Molins E, Serra P, et al. Anemia is a mortalitypredictor in hospitalized patients for COPD exacerbation. COPD 2012;9:243-50.
83. Boutou AK, Karrar S, Hopkinson NS, Polkey MI. Anemia and survival in chronic obstructive pulmonary disease: A dichotomous rather than a continuous predictor. Respiration 2013;85:126-31.
84. Rasmussen L, Christensen S, Lenler-Petersen P, Johnsen SP. Anemia and 90-daymortality in COPDpatients requiring invasive mechanical ventilation.ClinEpidemiol 2010;3:1-5.
85. Kollert F, Tippelt A, Müller C, Jörres RA, Porzelius C, Pfeifer M, et al. Hemoglobin levels above anemia thresholds are maximally predictive for long-term survival in COPD with chronic respiratory failure. Respir Care 2013;58:1204-12.
86. Upchurch GR Jr, Proctor MC, Henke PK, Zajkowski P, Riles EM, Ascher MS, et al. Predictors of severe morbidity and death after elective abdominal aortic aneurysmectomy in patients with chronic obstructive pulmonary disease. J VascSurg 2003;37:594-9.
87. Cappell MS, Nadler SC. Increased mortality of acute upper gastrointestinal bleeding in patients with chronic obstructive pulmonary disease. A case controlled, multiyear study of 53 consecutive patients. Dig Dis Sci 1995;40:256-62.
88. Schönhofer B, Wenzel M, Geibel M, Köhler D. Blood transfusion and lung function in chronically anemic patients with severe chronic obstructive pulmonary disease. Crit Care Med 1998;26:1824-8.
89. Schönhofer B, Böhrer H, Köhler D. Blood transfusion facilitating difficult weaning from the ventilator. Anaesthesia 1998;53:181-4.
90. Similowski T, Agustí A, MacNee W, Schönhofer B. The potential impact of anaemia of chronic diseasein COPD. EurRespir J 2006;27:390-6.
91. O'Neill BJ, Marlin GE, Streeter AM. Red-cell macrocytosis in chronic obstructive airway disease. Med J Aust 1972;1:283.
92. Tsantes AE, Papadhimitriou SI, Tassiopoulos ST, Bonovas S, Paterakis G, Meletis I, et al. Red cell macrocytosis in hypoxemic patients with chronic obstructive pulmonary disease. Respir Med 2004;98:1117-23.
93. Garcia-Pachon E, Padilla-Navas I. Red cell macrocytosis in COPD patients without respiratory insufficiency: A brief report. Respir Med 2007;101:349-52.
94. Seyhan EC, Özgül MA, Tutar N, Ömür I, Uysal A, Altin S. Red blood cell distribution and survival in patients with chronic obstructive pulmonary disease. COPD 2013;10:416-24.
95. Alexandre BM, Charro N, Blonder J, Lopes C, Azevedo P, Bugalho de Almeida A, et al. Profiling the erythrocyte membrane proteome isolated from patients diagnosed with chronic obstructive pulmonary disease. J Proteomics 2012;76:259-69.